Clinical Oncology
Volume 20, Issue 7 , Pages 513-516 , September 2008

Epirubicin/Vinorelbine Adjuvant Chemotherapy in Young Women with Breast Cancer is Associated with Preservation of Menstrual Function

Received 21 November 2007 ,Revised 25 March 2008 ,Accepted 27 March 2008.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2006;56(2):106–130
  2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;19(352):930–942
  3. Di Cosimo S, Alimonti A, Ferretti G, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol. 2004;15:1065–1071
  4. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718–1729
  5. Chua S, Smith IE, A'hern RP, et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial. Ann Oncol. 2005;16(9):1435–1441
  6. Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjostrom J, Kjaer M. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol. 2004;22(12):2313–2320
  7. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;1:105–109
  8. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:2651–2658
  9. Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol. 2005;23(25):6002–6008
  10. Martin M, Pienkowski T, Mackey J. Adjuvant docetaxel for node-positive breast cancer. New Engl J Med. 2005;352(22):2302–2313
  11. Goldhirsch A, Castiglione M, Gelber RD. Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases. Lancet. 1990;5(335):1099–1100
  12. Brusamolino E, Lunghi F, Orlandi E, et al. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologica. 2000;85(10):1032–1039
  13. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993;11(7):1245–1252
  14. Twelves CJ, Dobbs NA, Curnow A, et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer. 1994;70(5):990–993
  15. Vici P, Colucci G, Gebbia V, et al. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol. 2002;20(11):2689–2694
  16. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–4183
  17. Poole CJ, Earl HM, Dunn JA, et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Annual ASCO meeting 2003 [Abstract 13].

PII: S0936-6555(08)00205-7

doi: 10.1016/j.clon.2008.03.016

Clinical Oncology
Volume 20, Issue 7 , Pages 513-516 , September 2008

Article Tools